In Vitro Activity of Benzimidazole (SPR719) Against Clinical Isolates of Nontuberculous Mycobacteria With and Without Clarithromycin or Amikacin Resistance
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Limited data are available regarding the in vitro activity of SPR719, a derivative of benzimidazole, against diverse nontuberculous mycobacteria (NTM) species. We investigated the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of SPR719 against clinical NTM isolates, including clarithromycin- and amikacin-resistant strains. NTM isolates were obtained from patients with NTM-pulmonary disease caused by various NTM species, including Mycobacterium avium complex, M. abscessus (subspecies abscessus and massiliense), M. kansasii, and M. fortuitum. Regardless of clarithromycin or amikacin resistance, the MIC and MBC values of SPR719 were comparable among these major pathogenic NTM species. In over 70% of the isolates, the MIC values were ≤2 μg/mL with MBC values of ≤4 μg/mL. The MIC and MBC values of M. kansasii were relatively lower than those of the other species with little difference between them, demonstrating the bactericidal properties of SPR719. The in vitro activity of SPR719 against major clinical NTM species suggests that SPR719 can serve as a novel treatment option for NTM-pulmonary disease.
Abstract
Limited data are available regarding the in vitro activity of SPR719, a derivative of benzimidazole, against diverse nontuberculous mycobacteria (NTM) species. We investigated the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of SPR719 against clinical NTM isolates, including clarithromycin- and amikacin-resistant strains. NTM isolates were obtained from patients with NTM-pulmonary disease caused by various NTM species, including Mycobacterium avium complex, M. abscessus (subspecies abscessus and massiliense), M. kansasii, and M. fortuitum. Regardless of clarithromycin or amikacin resistance, the MIC and MBC values of SPR719 were comparable among these major pathogenic NTM species. In over 70% of the isolates, the MIC values were ≤2 μg/mL with MBC values of ≤4 μg/mL. The MIC and MBC values of M. kansasii were relatively lower than those of the other species with little difference between them, demonstrating the bactericidal properties of SPR719. The in vitro activity of SPR719 against major clinical NTM species suggests that SPR719 can serve as a novel treatment option for NTM-pulmonary disease.
참고문헌 (20)
- Prevots DR, "Epidemiology of human pulmonary infection with nontuberculous mycobacteria : a review", Clin Chest Med, 36, pp.13~34 (2015)
- Stout JE, "Update on pulmonary disease due to non-tuberculous mycobacteria", Int J Infect Dis, 45, pp.123~134 (2016)
- Adjemian J, "Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries", Am J Respir Crit Care Med, 185, pp.881~886 (2012)
- Haworth CS, "British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease(NTM-PD)", Thorax, 72(S2), pp.ii1~ii64 (2017)
- Daley CL, "Treatment of Nontuberculous Mycobacterial Pulmonary Disease : An Official ATS", ERS, IDSA Clinical Practice Guideline, pp.Clin Infect Dis, 2020[DOI]
- Keri RS, "Benzimidazole-core as an antimycobacterial agent", Pharmacol Rep, 68, pp.1254~1265 (2016)
- Gong Y, "Benzimidazole-based compounds kill Mycobacterium tuberculosis", Eur J Med Chem, 75, pp.336~353 (2014)
- Yoon YK, "Synthesis and evaluation of antimycobacterial activity of new benzimidazole aminoesters", Eur J Med Chem, 93, pp.614~624 (2015)
- Aragaw WW, "In vitro resistance against DNA gyrase inhibitor SPR719 in Mycobacterium avium and Mycobacterium abscessus", Microbiol Spectr, 10, pp.e0132121~ (2022)
- Nessar R, "Mycobacterium abscessus : a new antibiotic nightmare", J Antimicrob Chemother, 67, pp.810~818 (2012)
- Moon SM, "Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium complex lung disease", Antimicrob Agents Chemother, 60, pp.6758~6765 (2016)
- Choi H, "Clinical characteristics and treatment outcomes of patients with acquired macrolide-resistant Mycobacterium abscessus lung disease", Antimicrob Agents Chemother, 61, pp.e01146~ (2017)
- Choi H, "Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium massiliense lung disease", Antimicrob Agents Chemother, 61, pp.e02189~ (2017)
- Jhun BW, "Amikacin inhalation as salvage therapy for refractory nontuberculous mycobacterial lung disease", Antimicrob Agents Chemother, 62, pp.e00011-18~ (2018)
- Huh HJ, "GenoType NTM-DR performance evaluation for identification of Mycobacterium avium complex and Mycobacterium abscessus and determination of clarithromycin and amikacin resistance", J Clin Microbiol, 57, pp.e00516-19~ (2019)
- CLSI, "Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes; approved standard" (2018), Clinical and Laboratory Standards Institute
- CLSI, "Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes; approved standard" (2018), Clinical and Laboratory Standards Institute
- Pennings LJ, "The benzimidazole SPR719 shows promising concentration-dependent activity and synergy against nontuberculous mycobacteria", Antimicrob Agents Chemother, 65, pp.e02469-20~ (2021)
- Pidot SJ, "In vitro activity of SPR719 against Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera", PLoS Negl Trop Dis, 15, pp.e0009636~ (2021)
- Talley AK, "First-in-human evaluation of the safety, tolerability, and pharmacokinetics of SPR720, a novel oral bacterial DNA gyrase(GyrB)inhibitor for mycobacterial infections", Antimicrob Agents Chemother, 65, pp.e0120821~ (2021)